103 related articles for article (PubMed ID: 19232033)
1. Comparing clinical and economic characteristics between commercially-insured patients with diabetic neuropathy and demographically-matched diabetic controls.
Zhao Y; Ye W; Le TK; Boye KS; Holcombe JH; Swindle R
Curr Med Res Opin; 2009 Mar; 25(3):585-97. PubMed ID: 19232033
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of other diabetes-associated complications and comorbidities and its impact on health care charges among patients with diabetic neuropathy.
Zhao Y; Ye W; Boye KS; Holcombe JH; Hall JA; Swindle R
J Diabetes Complications; 2010; 24(1):9-19. PubMed ID: 18930413
[TBL] [Abstract][Full Text] [Related]
3. Healthcare charges and utilization associated with diabetic neuropathy: impact of Type 1 diabetes and presence of other diabetes-related complications and comorbidities.
Zhao Y; Ye W; Boye KS; Holcombe JH; Swindle R
Diabet Med; 2009 Jan; 26(1):61-9. PubMed ID: 19125762
[TBL] [Abstract][Full Text] [Related]
4. Clinical and economic burden of peripheral T-cell lymphoma in commercially insured patients in the United States: findings using real-world claims data.
Burudpakdee C; Lin HM; Wang W; Seetasith A; Zhu Y; Bonthapally V; Carson KR
J Med Econ; 2016 Oct; 19(10):965-72. PubMed ID: 27152635
[TBL] [Abstract][Full Text] [Related]
5. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
6. Impact of comorbid depression or anxiety on patterns of treatment and economic outcomes among patients with diabetic peripheral neuropathic pain.
Boulanger L; Zhao Y; Foster TS; Fraser K; Bledsoe SL; Russell MW
Curr Med Res Opin; 2009 Jul; 25(7):1763-73. PubMed ID: 19505204
[TBL] [Abstract][Full Text] [Related]
7. A retrospective study on the impact of comorbid depression or anxiety on healthcare resource use and costs among diabetic neuropathy patients.
Boulanger L; Zhao Y; Bao Y; Russell MW
BMC Health Serv Res; 2009 Jun; 9():111. PubMed ID: 19566952
[TBL] [Abstract][Full Text] [Related]
8. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
9. Healthcare costs and utilization for Medicare beneficiaries with Alzheimer's.
Zhao Y; Kuo TC; Weir S; Kramer MS; Ash AS
BMC Health Serv Res; 2008 May; 8():108. PubMed ID: 18498638
[TBL] [Abstract][Full Text] [Related]
10. Burden of illness in patients with possible Lennox-Gastaut syndrome: A retrospective claims-based study.
Reaven NL; Funk SE; Montouris GD; Saurer TB; Story TJ
Epilepsy Behav; 2018 Nov; 88():66-73. PubMed ID: 30241056
[TBL] [Abstract][Full Text] [Related]
11. Diabetic peripheral neuropathy: resource utilization and burden of illness.
Mehra M; Merchant S; Gupta S; Potluri RC
J Med Econ; 2014 Sep; 17(9):637-45. PubMed ID: 24888404
[TBL] [Abstract][Full Text] [Related]
12. Duloxetine compliance and its association with healthcare costs among patients with diabetic peripheral neuropathic pain.
Wu N; Chen S; Boulanger L; Fraser K; Bledsoe SL; Zhao Y
J Med Econ; 2009 Sep; 12(3):192-202. PubMed ID: 19705975
[TBL] [Abstract][Full Text] [Related]
13. Economic burden of sarcoidosis in a commercially-insured population in the United States.
Rice JB; White A; Lopez A; Conway A; Wagh A; Nelson WW; Philbin M; Wan GJ
J Med Econ; 2017 Oct; 20(10):1048-1055. PubMed ID: 28678623
[TBL] [Abstract][Full Text] [Related]
14. A retrospective, matched cohort study of potential drug-drug interaction prevalence and opioid utilization in a diabetic peripheral neuropathy population initiated on pregabalin or duloxetine.
Ellis JJ; Sadosky AB; Ten Eyck LL; Mudumby P; Cappelleri JC; Ndehi L; Suehs BT; Parsons B
BMC Health Serv Res; 2015 Apr; 15():159. PubMed ID: 25889173
[TBL] [Abstract][Full Text] [Related]
15. Medication adherence and healthcare costs among patients with diabetic peripheral neuropathic pain initiating duloxetine versus pregabalin.
Zhao Y; Sun P; Watson P
Curr Med Res Opin; 2011 Apr; 27(4):785-92. PubMed ID: 21303196
[TBL] [Abstract][Full Text] [Related]
16. Comparing common reasons for inpatient and outpatient visits between commercially-insured duloxetine or pregabalin initiators with fibromyalgia.
Zhao Y; Sun P; Bernauer M
J Pain Res; 2012; 5():443-51. PubMed ID: 23152695
[TBL] [Abstract][Full Text] [Related]
17. The health care status of the diabetic population as reflected by physician claims to a major insurer.
Rendell M; Kimmel DB; Bamisedun O; O'Donnell ET; Fulmer J
Arch Intern Med; 1993 Jun; 153(11):1360-6. PubMed ID: 8507126
[TBL] [Abstract][Full Text] [Related]
18. The quality of life and economic burden of neuropathy in diabetic patients in Germany in 2002--results from the Diabetic Microvascular Complications (DIMICO) study.
Happich M; John J; Stamenitis S; Clouth J; Polnau D
Diabetes Res Clin Pract; 2008 Aug; 81(2):223-30. PubMed ID: 18602714
[TBL] [Abstract][Full Text] [Related]
19. Healthcare utilization and costs in patients with tuberous sclerosiscomplex-related renal angiomyolipoma.
Song X; Liu Z; Cappell K; Gregory C; Said Q; Prestifilippo J; Charles H; Hulbert J; Bissler J
J Med Econ; 2017 Apr; 20(4):388-394. PubMed ID: 27998195
[TBL] [Abstract][Full Text] [Related]
20. Real-world economic burden of hematopoietic cell transplantation among a large US commercially insured population with hematologic malignancies.
Bonafede M; Richhariya A; Cai Q; Josephson NC; McMorrow D; Garfin PM; Perales MA
J Med Econ; 2017 Dec; 20(12):1244-1251. PubMed ID: 28782449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
